Last updated: 19 October 2021 at 6:46pm EST

Inc Cpmg Net Worth




The estimated Net Worth of Inc Cpmg is at least $371 Milion dollars as of 15 October 2021. Inc Cpmg owns over 683,871 units of Reata Pharmaceuticals Inc stock worth over $370,782,383 and over the last 8 years Inc sold RETA stock worth over $0.

Inc Cpmg RETA stock SEC Form 4 insiders trading

Inc has made over 21 trades of the Reata Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Inc bought 683,871 units of RETA stock worth $5,300,000 on 15 October 2021.

The largest trade Inc's ever made was buying 1,780,000 units of Reata Pharmaceuticals Inc stock on 17 July 2020 worth over $2,225,000. On average, Inc trades about 191,335 units every 82 days since 2016. As of 15 October 2021 Inc still owns at least 2,151,209 units of Reata Pharmaceuticals Inc stock.

You can see the complete history of Inc Cpmg stock trades at the bottom of the page.



What's Inc Cpmg's mailing address?

Inc's mailing address filed with the SEC is 2000 MCKINNEY AVE., STE 2125, , DALLAS, TX, 75201.

Insiders trading at Reata Pharmaceuticals Inc

Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy oraz Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.



What does Reata Pharmaceuticals Inc do?

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.



Complete history of Inc Cpmg stock trades at Apollo Endosurgery Inc i Reata Pharmaceuticals Inc

Osoba
Trans.
Transakcja
Łączna cena
Inc Cpmg
Kupować $5,300,000
15 Oct 2021
Inc Cpmg
Kupować $2,225,000
17 Jul 2020
Inc Cpmg
Kupować $7,359,894
18 Nov 2019
Inc Cpmg
Kupować $6,584,173
10 Dec 2018
Inc Cpmg
Kupować $483,990
29 Dec 2017
Inc Cpmg
Kupować $705,296
26 Dec 2017
Inc Cpmg
Kupować $4,958,000
15 Dec 2017
Inc Cpmg
Kupować $203,994
30 Dec 2016
Inc Cpmg
Kupować $3,787,671
16 Dec 2016
Inc Cpmg
Kupować $3,787,671
16 Dec 2016
Inc Cpmg
Kupować $191,736
14 Dec 2016
Inc Cpmg
Kupować $191,736
14 Dec 2016
Inc Cpmg
Kupować $5,264,398
16 Aug 2016
Inc Cpmg
Kupować $5,264,398
16 Aug 2016
Inc Cpmg
Kupować $3,255,788
28 Jun 2016
Inc Cpmg
Kupować $3,255,788
28 Jun 2016
Inc Cpmg
Kupować $1,413,742
24 Jun 2016
Inc Cpmg
Kupować $1,413,742
24 Jun 2016
Inc Cpmg
Kupować $425,545
6 Jun 2016
Inc Cpmg
Kupować $3,194,723
1 Jun 2016
Inc Cpmg
Kupować $107,830
1 Jun 2016


Reata Pharmaceuticals Inc executives and stock owners

Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include: